Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor

Ribociclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is used in combination with an aromatase inhibitor in the first-line setting for advanced or metastatic hormone receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We report two cases of drug-induced vitiligo-like depigmentation (DI-VLD) associated with ribociclib. The awareness of this side effect is important given the increasing use of this drug and others with a similar mechanism of action.

Automated summary

Ribociclib, an inhibitor of CDK 4/6 used in breast cancer treatment, can cause drug-induced vitiligo-like depigmentation. Awareness of this side effect is crucial due to the increasing use of drugs with similar mechanisms of action.